Evidence map›Paper›PMID 35816400›Full record

ArticleCancer science2022

Basal extrusion of single-oncogenic mutant cells induces dome-like structures with altered microenvironments.

Takanobu Shirai, Miho Sekai, Kei Kozawa, Nanami Sato, Nobuyuki Tanimura, Shunsuke Kon, Tomohiro Matsumoto, Takeru Murakami, Shoko Ito, Andrew Tilston-Lunel and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Takanobu ShiraiDepartment of Molecular Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Miho SekaiDepartment of Molecular Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kei KozawaDepartment of Molecular Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Nanami SatoDepartment of Molecular Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Nobuyuki TanimuraDepartment of Molecular Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Shunsuke KonDivision of Molecular Oncology, Institute for Genetic Medicine, Hokkaido University Graduate School of Chemical Sciences and Engineering, Sapporo, Japan.ORCID https://orcid.org/0000-0002-2693-6128
Tomohiro MatsumotoDivision of Molecular Oncology, Institute for Genetic Medicine, Hokkaido University Graduate School of Chemical Sciences and Engineering, Sapporo, Japan.
Takeru MurakamiDepartment of Molecular Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Shoko ItoDepartment of Molecular Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Andrew Tilston-LunelDepartment of Biochemistry, Boston University School of Medicine, Boston, Massachusetts, USA.
Xaralabos VarelasDepartment of Biochemistry, Boston University School of Medicine, Boston, Massachusetts, USA.
Yasuyuki FujitaDepartment of Molecular Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID https://orcid.org/0000-0002-5875-7052
Kyoto University · JPHokkaido University · JPBoston University · US

Funding

Defining epithelial polarity cues that direct cell fateR01HL124392 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI VARELAS, XARALABOS · 2014 to 2024
$4.5M
Japan Science and Technology Agency (JST) JPMJPS2022Japan Society for the Promotion of Science (JSPS) 21H05039Japan Society for the Promotion of Science (JSPS) 21H05285A01Japan Society for the Promotion of Science (JSPS) JP19J11375JSPS Bilateral Joint Research Projects (The Royal Society) JPJSBP1 20215703JSPS Bilateral Joint Research Projects (The Royal Society) JPJSBP1 20K21411Kyoto University Live Imaging CenterMitsubishi FoundationNHLBI NIH HHS R01 HL124392SAN-ESU GIKEN CO. LTDShiseido Female Researcher Science GrantTakeda Science Foundation
6 · The paper itself

Abstract

At the initial stage of carcinogenesis, oncogenic transformation occurs in single cells within epithelial layers. However, the behavior and fate of the newly emerging transformed cells remain enigmatic. Here, using originally established mouse models, we investigate the fate of RasV12-transformed cells that appear in a mosaic manner within epithelial tissues. In the lung bronchial epithelium, most majority of RasV12-transformed cells are apically extruded, whereas noneliminated RasV12 cells are often basally delaminated leading to various noncell-autonomous changes in surrounding environments; macrophages and activated fibroblasts are accumulated, and normal epithelial cells overlying RasV12 cells overproliferate and form a convex multilayer, which is termed a 'dome-like structure'. In addition, basally extruded RasV12 cells acquire certain features of epithelial-mesenchymal transition (EMT). Furthermore, the expression of COX-2 is profoundly elevated in RasV12 cells in dome-like structures, and treatment with the COX inhibitor ibuprofen suppresses the recruitment of activated fibroblasts and moderately diminishes the formation of dome-like structures. Therefore, basal extrusion of single-oncogenic mutant cells can induce a tumor microenvironment and EMT and generate characteristic precancerous lesions, providing molecular insights into the earlier steps of cancer development.

Indexed as

Cell Transformation, NeoplasticEpithelial CellsAnimalsDogsEpitheliumMadin Darby Canine Kidney CellsMiceOncogenesTumor Microenvironmentdome-like structureepithelial-mesenchymal transitioninitial stage of carcinogenesisRasV12tumor microenvironment

Identifiers

PMID35816400
PMCPMC9633292
OpenAlexW4285013413

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.